Latanea

Latanoprost, the active ingredient in Latanea, is a prostaglandin analog presented as an eye drop for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost acts on the prostaglandin pathway to reduce intra‑ocular pressure in glaucoma‑related conditions.

Open‑angle glaucoma: reduces intra‑ocular pressure to help prevent optic nerve damage. Ocular hypertension: lowers eye pressure to decrease the risk of developing glaucoma.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Eye irritation or foreign‑body sensation - Blurred vision - Increased brown pigmentation of the iris - Growth of eyelashes - Mild ocular discomfort

Serious or Rare Side Effects: - Uveitis or severe eye inflammation - Allergic contact dermatitis of the eyelids - Macular edema leading to vision changes - Sudden loss of vision - Severe ocular pain - Systemic hypersensitivity reactions

Before initiating therapy, consider the following precautions.

Monitor intra‑ocular pressure regularly: ensure therapeutic effect and detect over‑reduction. Assess for ocular infections: avoid use if active infection is present. Use with caution in patients with a history of uveitis: may exacerbate inflammation. Avoid in individuals with known hypersensitivity to prostaglandin analogs: risk of allergic reaction. Evaluate corneal health: pre‑existing corneal disease may worsen. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other intra‑ocular pressure‑lowering eye drops (e.g., timolol) may cause excessive pressure reduction. - Combination with ocular anesthetic agents may increase ocular irritation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effect. - Alpha‑agonist eye drops: watch for excessive pressure lowering. - Systemic non‑steroidal anti‑inflammatory drugs: may diminish prostaglandin efficacy. - Anticholinergic medications: monitor for changes in ocular surface.